FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892056543> ?p ?o ?g. }

• W2892056543 abstract "Traumatic brain injury (TBI) is a major cause of death and disability, but there are currently no therapies with proven efficacy for optimizing regeneration of repair during rehabilitation. Using standard stimulation tests, as many as 40-50% of survivors of severe TBI have deficiency of one or more pituitary hormones. Of these, the somatotropic axis is the most commonly affected, with Growth Hormone (GH) deficiency affecting ~20% of persons with severe TBI. Treatment with recombinant human Growth Hormone (rhGH) is generally effective in reversing the effects of acquired GH deficiency, but there is no evidence documenting functional or neurocognitive improvement after GH replacement in TBI patients. As a consequence, screening for GH deficiency and GH replacement when deficiency is found is not routinely performed as part of the rehabilitation of TBI survivors. Given that most of the recovery after TBI occurs within the first 6-12 months after injury and IGF-1 and GH are part of a coordinated restorative neurotrophic system, we hypothesized that patients will optimally benefit from GH therapy during the window of maximal neuroregenerative activity. We performed a Phase IIa, randomized, double-blind, placebo-controlled feasibility trial of recombinant human Growth Hormone (rhGH), starting at discharge from an inpatient rehabilitation unit, with follow up at 6 and 12 months. Our primary hypothesis was that treatment with rhGH in the subacute period would result in improved functional outcomes 6 months after injury. Our secondary hypothesis proposed that treatment with rhGH would increase IGF-1 levels and be well tolerated. Sixty-three subjects were randomized, and 40 completed the trial. At baseline, there was no correlation between IGF-1 levels and peak GH levels after L-arginine stimulation. IGF-1 levels increased after rhGH treatment, but it took longer than 1 month for levels to be higher than for placebo-treated patients. rhGH therapy was well-tolerated. The rhGH group was no different from placebo in the Disability Rating Scale, Glasgow Outcome Scale-Extended, or neuropsychological function. However, a trend toward greater improvement from baseline in Functional Independence Measure (FIM) was noted in the rhGH treated group. Future studies should include longer treatment periods, faster titration of rhGH, and larger sample sizes." @default.
• W2892056543 created "2018-09-27" @default.
• W2892056543 creator A5009630321 @default.
• W2892056543 creator A5012039333 @default.
• W2892056543 creator A5017306415 @default.
• W2892056543 creator A5029617270 @default.
• W2892056543 creator A5050856857 @default.
• W2892056543 creator A5055037280 @default.
• W2892056543 creator A5067785191 @default.
• W2892056543 creator A5088324489 @default.
• W2892056543 date "2018-09-10" @default.
• W2892056543 modified "2023-10-16" @default.
• W2892056543 title "Phase 2 Randomized, Placebo-Controlled Clinical Trial of Recombinant Human Growth Hormone (rhGH) During Rehabilitation From Traumatic Brain Injury" @default.
• W2892056543 cites W1511713572 @default.
• W2892056543 cites W1564669112 @default.
• W2892056543 cites W1986472833 @default.
• W2892056543 cites W2006074731 @default.
• W2892056543 cites W2007129533 @default.
• W2892056543 cites W2007863970 @default.
• W2892056543 cites W2009658244 @default.
• W2892056543 cites W2015253115 @default.
• W2892056543 cites W2016016046 @default.
• W2892056543 cites W2018949167 @default.
• W2892056543 cites W2022644027 @default.
• W2892056543 cites W2047075116 @default.
• W2892056543 cites W2053845533 @default.
• W2892056543 cites W2058868308 @default.
• W2892056543 cites W2059124935 @default.
• W2892056543 cites W2073266477 @default.
• W2892056543 cites W2077462719 @default.
• W2892056543 cites W2077490225 @default.
• W2892056543 cites W2077848651 @default.
• W2892056543 cites W2082610802 @default.
• W2892056543 cites W2086804271 @default.
• W2892056543 cites W2090627812 @default.
• W2892056543 cites W2097530528 @default.
• W2892056543 cites W2097891309 @default.
• W2892056543 cites W2100240119 @default.
• W2892056543 cites W2100488282 @default.
• W2892056543 cites W2122104062 @default.
• W2892056543 cites W2141177022 @default.
• W2892056543 cites W2146352480 @default.
• W2892056543 cites W2621218709 @default.
• W2892056543 cites W2770565967 @default.
• W2892056543 cites W2798063557 @default.
• W2892056543 doi "https://doi.org/10.3389/fendo.2018.00520" @default.
• W2892056543 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6139310" @default.
• W2892056543 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30250451" @default.
• W2892056543 hasPublicationYear "2018" @default.
• W2892056543 type Work @default.
• W2892056543 sameAs 2892056543 @default.
• W2892056543 citedByCount "10" @default.
• W2892056543 countsByYear W28920565432019 @default.
• W2892056543 countsByYear W28920565432020 @default.
• W2892056543 countsByYear W28920565432021 @default.
• W2892056543 countsByYear W28920565432022 @default.
• W2892056543 countsByYear W28920565432023 @default.
• W2892056543 crossrefType "journal-article" @default.
• W2892056543 hasAuthorship W2892056543A5009630321 @default.
• W2892056543 hasAuthorship W2892056543A5012039333 @default.
• W2892056543 hasAuthorship W2892056543A5017306415 @default.
• W2892056543 hasAuthorship W2892056543A5029617270 @default.
• W2892056543 hasAuthorship W2892056543A5050856857 @default.
• W2892056543 hasAuthorship W2892056543A5055037280 @default.
• W2892056543 hasAuthorship W2892056543A5067785191 @default.
• W2892056543 hasAuthorship W2892056543A5088324489 @default.
• W2892056543 hasBestOaLocation W28920565431 @default.
• W2892056543 hasConcept C118552586 @default.
• W2892056543 hasConcept C126322002 @default.
• W2892056543 hasConcept C142724271 @default.
• W2892056543 hasConcept C168563851 @default.
• W2892056543 hasConcept C169900460 @default.
• W2892056543 hasConcept C172467417 @default.
• W2892056543 hasConcept C1862650 @default.
• W2892056543 hasConcept C187212893 @default.
• W2892056543 hasConcept C204787440 @default.
• W2892056543 hasConcept C27081682 @default.
• W2892056543 hasConcept C2778818304 @default.
• W2892056543 hasConcept C2779952775 @default.
• W2892056543 hasConcept C2781017439 @default.
• W2892056543 hasConcept C2984496839 @default.
• W2892056543 hasConcept C71315377 @default.
• W2892056543 hasConcept C71924100 @default.
• W2892056543 hasConceptScore W2892056543C118552586 @default.
• W2892056543 hasConceptScore W2892056543C126322002 @default.
• W2892056543 hasConceptScore W2892056543C142724271 @default.
• W2892056543 hasConceptScore W2892056543C168563851 @default.
• W2892056543 hasConceptScore W2892056543C169900460 @default.
• W2892056543 hasConceptScore W2892056543C172467417 @default.
• W2892056543 hasConceptScore W2892056543C1862650 @default.
• W2892056543 hasConceptScore W2892056543C187212893 @default.
• W2892056543 hasConceptScore W2892056543C204787440 @default.
• W2892056543 hasConceptScore W2892056543C27081682 @default.
• W2892056543 hasConceptScore W2892056543C2778818304 @default.
• W2892056543 hasConceptScore W2892056543C2779952775 @default.
• W2892056543 hasConceptScore W2892056543C2781017439 @default.
• W2892056543 hasConceptScore W2892056543C2984496839 @default.
• W2892056543 hasConceptScore W2892056543C71315377 @default.
• W2892056543 hasConceptScore W2892056543C71924100 @default.
• W2892056543 hasFunder F4320337604 @default.

• next